COMP <GO>
TEVA vs RPRX // EV/EBITDA & P/E VALUATION
Teva Pharmaceutical Industries Limited (NYSE) VS. Royalty Pharma plc (Class A) (NASDAQ) • 15-METRIC TALLY: TEVA 5
— RPRX 6
▲ EV/EBITDA & P/E VALUATION LEADER: TEVA
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
valuation
20.8x
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
valuation
27.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. RPRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | RPRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 7.00% | +2.40 | TEVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.8x | 27.8x | -7.00 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 6.29% | -4.48 | RPRX | /fcf-yield <GO> |
| Operating Margin | 12.50% | 65.60% | -53.10 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 32.40% | -24.20 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 5.10% | -0.80 | RPRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 2.90 | -1.88 | RPRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 68.6 | -10.00 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.94 | +0.06 | TEVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 45.8x | -13.90 | TEVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $37.91B | $10.41B | TEVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | RPRX REV | TEVA GROSS % | RPRX GROSS % | TEVA FCF | RPRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $2.38B | 51.8% | — | $872.4M | $2.38B |
| FY 2024 | $16.54B | $2.26B | 48.7% | — | $502.5M | $2.67B |
| FY 2023 | $15.85B | $2.35B | — | — | $654.9M | $2.88B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
RPRX // BETA 0.94